Donanemab-mediated amyloid plaque clearance reduces microglial activation and neuronal injury, attenuating trans-synaptic tau propagation. With reduced neuronal damage, p-tau217 release declines. This mechanistic pathway is biologically plausible but the causal chain (amyloid clearance → reduced neuronal injury → decreased p-tau217) remains unproven. Correlation of temporal sequence does not equal mechanistic causation.
Curated pathway from expert analysis
flowchart TD
A["Target Gene: NA - Mechanistic hypothesis"]
B["Molecular Mechanism<br/>Pathway Activation"]
C["Cellular Phenotype<br/>Neuronal / Glial Response"]
D["Network Effect<br/>Circuit-Level Consequence"]
E["Disease Relevance<br/>Neurodegeneration Link"]
A --> B --> C --> D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#81c784,color:#81c784No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for NA yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NA - Mechanistic hypothesis.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF participants with early Alzheimer's disease receive donanemab treatment and achieve ≥50% reduction in cortical amyloid PET standardized uptake value ratio (Centiloids <25) as measured at 6 months, | CSF p-tau217 levels will decrease ≥30% from baseline within 12 months, correlating with amyloid clearance magnitude | — no observation — | pending | 0.45 |
| IF amyloid plaque clearance is achieved via donanemab treatment, THEN the reduction in CSF neurofilament light chain (NfL) levels (marker of reduced axonal injury) will statistically mediate ≥40% of t | CSF NfL will mediate ≥40% of the relationship between amyloid clearance and p-tau217 reduction, with mediated effect significant at p<0.05 | — no observation — | pending | 0.35 |